Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. in vitro migration and invasion assays
Show results for
Products
Services
Software
Applications

Companies

News
Articles
Downloads
Videos

Refine by
Date

  • Older

In Vitro Migration And Invasion Assays Articles & Analysis

18 news found

Customer Success Story: Why Clean Cells Chose VIPS PRO: The Need for Clonality & GMP Compatibility

Customer Success Story: Why Clean Cells Chose VIPS PRO: The Need for Clonality & GMP Compatibility

Introduction We recently sat down with one of our valued customers, Dr Alexis Rossignol (Clean Cells), to discuss his experience with VIPS PRO, our cutting-edge technology designed to streamline and enhance the early stages of cell line development. This interview provides insight into Clean Cells’ quest to automate and increase single-cell seeding while having undisputable proof ...

ByAdvanced Instruments


Sirenas and Hume Supernatural Enter Into Strategic Collaboration to Create Science-Backed Personal Care Products

Sirenas and Hume Supernatural Enter Into Strategic Collaboration to Create Science-Backed Personal Care Products

Sirenas, a chemical discovery company harnessing computational metabolomics for “Natural Product” drug discovery, and Hume Supernatural, Inc. (“Hume”), a leading personal care product company, announced today that the companies have entered into a collaboration to bring new natural ingredients from diverse marine and terrestrial sources into the personal care space. The ...

BySirenas


Structure-Based Search for Novel Antihypercholestrolemic Agents

Structure-Based Search for Novel Antihypercholestrolemic Agents

DESCRIPTION (provided by applicant): Heart disease is the leading cause of death for both men and women in the US, accounting for nearly 40% of all annual deaths. A high cholesterol level is a well-known risk factors for heart disease. Although blood cholesterol can be lowered using a number of marketed drugs, of which statins are the leading drugs, only 38% of patients taking these drugs are ...

ByShifa Biomedical Corporation


Aesther Healthcare Acquisition Corp. Has Entered Into an Agreement and Plan of Merger with Ocean Biomedical, Inc., a Next-Generation Biopharma Company, to List on NASDAQ

Aesther Healthcare Acquisition Corp. Has Entered Into an Agreement and Plan of Merger with Ocean Biomedical, Inc., a Next-Generation Biopharma Company, to List on NASDAQ

Ocean Biomedical’s innovative business model bridges the ‘bench-to-bedside’ gap by accelerating the commercialization of innovative assets from research universities and medical centers. Ocean Biomedical’s initial core portfolios in oncology, fibrosis, and infectious diseases – all based on new target discoveries enabling first-in-class drug and vaccine ...

ByOcean Biomedical


Affimed Presents Preclinical Data of Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA)

Affimed Presents Preclinical Data of Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA)

AFM28 induced potent, effective, and specific anti-tumor activity against CD123-positive cells irrespective of mutational status Study demonstrated specific anti-tumor response even at low levels of CD123 expression with no evidence for off-target cytotoxic activity towards CD123-negative healthy bone marrow progenitors In vivo studies of an AML murine model demonstrated anti-tumor efficacy; ...

ByAffimed GmbH


Onconova Therapeutics Announces Abstract At The ASCO Annual Meeting Highlighting Narazaciclib’s Differentiated Inhibitory And Improved Safety Profile In Preclinical Models

Onconova Therapeutics Announces Abstract At The ASCO Annual Meeting Highlighting Narazaciclib’s Differentiated Inhibitory And Improved Safety Profile In Preclinical Models

Featured in the abstract are preclinical data from in vitro and cell-based assays that demonstrate how narazaciclib’s inhibitory profile differentiates it from the FDA-approved CDK4/6 inhibitors palbociclib, ribociclib, and abemaciclib. ...

ByTraws Pharma


Pronalyse Unveils Therapeutic Enzyme Characterization Service for Your Drug Development

Pronalyse Unveils Therapeutic Enzyme Characterization Service for Your Drug Development

Pronalyse, a division of Creative Proteomics, is an integrated CRO company with rich experience in providing drug development services. To ensure drug identity, strength, potency, purity, and safety, Creative Proteomics Pronalyse announced the launch of therapeutic enzyme characterization services. Enzymes play a major role in the pharmaceutical industry today due to their ability to ...

ByCreative Proteomics


Obsidian Therapeutics to Present Preclinical Data from cytoTIL15™ Program at the American Associate of Cancer Research (AACR) Annual Meeting 2022

Obsidian Therapeutics to Present Preclinical Data from cytoTIL15™ Program at the American Associate of Cancer Research (AACR) Annual Meeting 2022

Obsidian Therapeutics, Inc., a biotechnology company pioneering engineered cell and gene therapies, today announced it will present preclinical data highlighting its cytoTIL15™ program during a poster session at the upcoming AACR Annual Meeting 2022. The abstract title has been posted to the AACR Online Itinerary Planner, will be published in the online Proceedings of the AACR, and is ...

ByObsidian Therapeutics, Inc.


Araris Biotech AG Presents Preclinical Data Highlighting Anti-CD79b ADC Program and Late-Breaking Data on Nectin-4 ADC at the American Association for Cancer Research (AACR) 2022 Annual Meeting

Araris Biotech AG Presents Preclinical Data Highlighting Anti-CD79b ADC Program and Late-Breaking Data on Nectin-4 ADC at the American Association for Cancer Research (AACR) 2022 Annual Meeting

Araris Biotech AG, a company pioneering a proprietary antibodydrug conjugate (ADC)-linker technology, today announced the company will deliver a poster presentation and an oral presentation at this year’s American Association for Cancer Research (AACR) 2022 Annual Meeting, being held April 8-13, 2022, in New Orleans, Louisiana. The poster presentation highlights the company’s ...

ByAraris Biotech AG


Araris Biotech AG Presents Preclinical Data Highlighting Anti-CD79b ADC Program and Late-Breaking Data on Nectin-4 ADC at the American Association for Cancer Research (AACR) 2022 Annual Meeting

Araris Biotech AG Presents Preclinical Data Highlighting Anti-CD79b ADC Program and Late-Breaking Data on Nectin-4 ADC at the American Association for Cancer Research (AACR) 2022 Annual Meeting

Araris Biotech AG, a company pioneering a proprietary antibodydrug conjugate (ADC)-linker technology, today announced the company will deliver a poster presentation and an oral presentation at this year’s American Association for Cancer Research (AACR) 2022 Annual Meeting, being held April 8-13, 2022, in New Orleans, Louisiana. The poster presentation highlights the company’s ...

ByAraris Biotech AG


Obsidian Therapeutics to Present In Vivo Anti-TumorEfficacy Data from Novel Engineered cytoTIL15 Program at SITC 2021

Obsidian Therapeutics to Present In Vivo Anti-TumorEfficacy Data from Novel Engineered cytoTIL15 Program at SITC 2021

Obsidian Therapeutics, Inc., a biotechnology company pioneering engineered cell and gene therapies, today announced that the Company will present preclinical in vivo anti-tumor efficacy against melanoma data for its cytoTIL15™ program at the upcoming Annual Meeting of the Society for Immunotherapy of Cancer (SITC). The event will be hosted live in Washington, D.C. and virtually from ...

ByObsidian Therapeutics, Inc.


Altis Biosystems Announces New Research Funding Initiative

Altis Biosystems Announces New Research Funding Initiative

Durham, NC (September 16, 2021) – Altis Biosystems, Inc., developer of RepliGut®, a technology platform that produces a layer of primary human intestinal stem and/or differentiated cells of either the small intestine or colon, announced today a Research Funding Initiative focused on one unifying purpose: To accelerate research into complex diseases and aid researchers in unlocking ...

ByAltis Biosystems


Qualigen Therapeutics, Inc. Announces Submission of Investigational New Drug (IND) Application for QN-165, for the Treatment of COVID-19

Qualigen Therapeutics, Inc. Announces Submission of Investigational New Drug (IND) Application for QN-165, for the Treatment of COVID-19

Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral diseases, announced today the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for Qualigen's QN-165 with an initial target indication for the treatment of COVID-19 in hospitalized patients. ...

ByQualigen Therapeutics, Inc.


StemBioSys and Cartox Announce Publication of Research Demonstrating CELLvo™ Matrix Plus Significantly Enhances the Functionality of hiPSC Cardiomyocytes

StemBioSys and Cartox Announce Publication of Research Demonstrating CELLvo™ Matrix Plus Significantly Enhances the Functionality of hiPSC Cardiomyocytes

StemBioSys, Inc. (StemBioSys) and CarTox, Inc. (Cartox) announced today the publication of research in Nature Scientific Reports demonstrating that CELLvo™ Matrix Plus, an extracellular matrix (ECM) technology derived from human perinatal stem cells, supports rapid functional and structural maturation of human induced pluripotent stem cell derived cardiomyocytes (hiPSC-CMs) in culture and ...

ByStemBioSys, Inc.


Insilico partners with Taisho on end-to-end AI-powered senolytic drug discovery

Insilico partners with Taisho on end-to-end AI-powered senolytic drug discovery

Thursday, October 15, 2020 (9 am ET) - Insilico Medicine announced today that Taisho Pharmaceutical Co., Ltd. and Insilico have entered into a research collaboration to identify novel therapeutics against aging. Insilico Medicine will utilize both the target discovery and generative chemistry parts of its Pharma.AI platform in this collaboration. It will use its proprietary Pandomics Discovery ...

ByInsilico Medicine


Oligomerix Receives $3.19 Million NIH Commercialization Readiness Pilot Grant for Alzheimer`s Disease Therapy

Oligomerix Receives $3.19 Million NIH Commercialization Readiness Pilot Grant for Alzheimer`s Disease Therapy

Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for Alzheimer’s disease (AD) and related neurodegenerative disorders, today announced that the company was awarded a $3.19 million grant from the National Institute on Aging (NIA) at National Institutes of Health (NIH). The three-year SBIR/STTR Commercialization Readiness Pilot ...

ByOligomerix, Inc.


Accuracy of comet measurements in image analysis systems

Accuracy of comet measurements in image analysis systems

If you are scoring comets using image analysis, you will want to be confident that the results you are getting are accurate. Comet Assay IV from Perceptive Instruments has a unique scoring method that has been validated both in-house and by many of the world’s leading pharmaceutical organisations and CROs. As part of the JaCVAM initiative to validate the in vivo and in vitro comet assays, ...

ByInstem Group


EU project shows eating right does the body good

Fruits, vegetables and nuts are just some of the foods that form part of a group of antioxidant chemical compounds called flavonoids. There is growing evidence that flavonoids, part of the polyphenols group, keeps humans healthy, fighting off cardiovascular disease, cancer and degenerative diseases. FLORA, a EUR 3.3 million EU-funded project, is helping people understand the link between diet and ...

ByEuropean Commission, Directorate General for Research & Innovation

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT